Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
This trial is active, not recruiting.
|Treatment||ablation with the nanoknife low energy direct current (ledc) system|
|Start date||February 2010|
|End date||October 2011|
|Trial size||25 participants|
|Trial identifier||NCT01078415, ONC-205|
The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Villejuif, France||L'institut de cancerologie Gustave Roussy||no longer recruiting|
|Paris, France||Hopital Beaujon||no longer recruiting|
|Magdeburg, Germany||Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin||no longer recruiting|
|Pisa, Italy||University of Pisa School of Medicine||no longer recruiting|
|Naples, Italy||Istituto Nazionale Tumori - Fondazione Pascale||no longer recruiting|
|Barcelona, Spain||Barcelona Clinic Liver Cancer Group, Hospital Clinic i Provincial de Barcelona||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.
time frame: 30 days (+/- 3 days) post treatment
Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.
time frame: Immediately post treatment to 2 years post treatment
Male or female participants at least 18 years old.
Inclusion Criteria: - HCC diagnosed by positive biopsy or non-invasive criteria, - not suitable for surgical resection or transplantation, - have at least one, but less than or equal to 3 tumors, - of the tumour(s) identified, each tumor must be ≤ 3 cm in diameter, - Child-Pugh class A, - Eastern Cooperative Oncology Group (ECOG) score of 0, - American Society of Anaesthesiologists (ASA) score ≤ 3, - a prothrombin time ratio > 50%, - platelet count > 50x109/L, - ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure, - are able to comprehend and willing to sign the written informed consent form (ICF), - have a life expectancy of at least 3 months. Exclusion Criteria: - eligible for surgical treatment or transplantation for HCC, - presence of vascular invasion or extrahepatic metastases, - received previous treatment for HCC, - HCC developed on an already transplanted liver, - cardiac insufficiency, ongoing coronary artery disease or arrhythmia, - any active implanted device (eg Pacemaker), - women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception, - have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System, - are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
|Official title||A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)|
|Principal investigator||Riccardo Lencioni, MD|
Call for more information